# Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis

> **NCT05138133** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 359 (actual)

## Conditions studied

- Lupus Nephritis

## Interventions

- **DRUG:** Anifrolumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05138133
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-02-15
- **Primary completion:** 2027-02-26
- **Final completion:** 2028-12-05
- **Target enrollment:** 359 (ACTUAL)
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05138133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05138133, "Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05138133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*